AUR103 for Advanced Neuroendocrine Tumors After Prior Treatment
Part of Cancer clinical trials.
This trial tests a new drug called AUR103 in patients with advanced neuroendocrine tumors (slow-growing cancers of hormone-producing cells) that have grown despite previous cancer treatment. The study aims to see if AUR103 can slow or stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and in good enough health to tolerate treatment (ECOG performance status 0–1, meaning you can do most daily activities)
- You have a confirmed diagnosis of well or moderately differentiated neuroendocrine tumor that is advanced (spread or cannot be surgically removed)
- Your cancer has progressed after at least one prior treatment, and you must have received at least one FDA-approved NET drug (everolimus, sunitinib, cabozantinib, or Lu177 dotatate)
- Your blood counts and organ function (liver, kidney) must be adequate based on recent lab tests
- You have measurable disease on imaging that doctors can track during the study
- You cannot have had cancer-fighting treatments (except somatostatin analogs, which are allowed) in the past 28 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests RYZ101 versus standard of care in people with inoperable, well-differentiated SSTR-positive GI or pancreas neuroendocrine tumors (NETs) that keep growing after Lu-177 SSA. It may help by improving tumor control after your prior targeted radiation treatment.
This trial tests a new drug called CRN09682 for people with neuroendocrine tumors (NETs) or other solid tumors that have grown despite treatment and show a specific marker on scans. The goal is to see if the drug is safe and works against these cancers.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This early-phase study tests whether AUR107 is safe and may help shrink or control advanced solid tumors that have come back or progressed. You may be considered if standard treatments no longer work and you meet specific blood, organ, and health requirements.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This phase 3 trial tests a radioactive drug (177Lu-DOTATATE) against a long-acting medication (Octreotide LAR) for people with advanced neuroendocrine tumors (NETs) that have grown despite standard treatment. The study aims to see which treatment works better and is safer.
Hear when a new Neuroendocrine (NE) Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.